5:31 PM
 | 
Jan 16, 2013
 |  BC Extra  |  Company News

FDA, EMA accept applications to expand Tysabri's label

Biogen Idec Inc. (NASDAQ:BIIB) and partner Elan Corp. plc (NYSE:ELN) said FDA and EMA accepted for review regulatory applications to expand the label of multiple sclerosis (MS) drug Tysabri natalizumab. The partners are seeking approval for Tysabri as first-line treatment for relapsing forms of MS in...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >